Abciximab 143653-53-6
Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa.[citation needed]
read more [+]| Systematic (IUPAC) name: | |
|---|---|
| Abciximab CAS number: | 143653-53-6 |
| ATC code: | B01AC13 |
| PubChem: | BTD00041 |
| DrugBank: | BTD00041 |
| Formula: | C6462H9964N1690O2049S48 |
| Molecular mass: | 145651.1 g/mol |
| Abciximab Assay/Purity: | Typically NLT 98% |
